OBJECTIVES: Esophagectomy is the standard treatment for T1 esophageal cancer (EC). Interest in endoscopic therapies, particularly for T1 EC, is increasing. We evaluated the long-term outcomes after esophagectomy and examined the pathologic features of T1 cancer to determine the suitability for potential endoscopic therapy. METHODS: We reviewed the outcomes of esophagectomy in 100 consecutive patients with T1 EC. The primary end points studied were overall survival (OS) and disease-free survival (DFS). In addition to detailed pathology review, we evaluated prognostic variables associated with survival. RESULTS: Esophagectomy was performed in 100 patients (79 men, 21 women; median age, 68 years) for T1 EC, comprising adenocarcinoma, 91; squamous, 9; intramucosal (T1a), 29; and submucosal (T1b), 71. The 30-day mortality was 0%. Resection margins were microscopically negative in 99 patients (99%). N1 disease was present in 21 (T1a, 2 of 29 [7%]; T1b, 19 of 71 [27%]), associated high-grade dysplasia in 64 (64%), and angiolymphatic invasion in 19 (19%). At a median follow-up of 66 months, estimated 5-year OS was 62% and 3-year DFS was 80% for all patients (including N1). Nodal status and tumor size were significantly associated with OS and DFS, respectively. CONCLUSIONS: Esophagectomy can be performed safely in patients with T1 EC with good long-term results. Many patients with T1 EC have several risk factors that may preclude adequate treatment with endoscopic therapy. Further prospective studies are required to evaluate endoscopic therapies. Esophagectomy should continue to remain the standard treatment in patients with T1 EC.
OBJECTIVES: Esophagectomy is the standard treatment for T1 esophageal cancer (EC). Interest in endoscopic therapies, particularly for T1 EC, is increasing. We evaluated the long-term outcomes after esophagectomy and examined the pathologic features of T1 cancer to determine the suitability for potential endoscopic therapy. METHODS: We reviewed the outcomes of esophagectomy in 100 consecutive patients with T1 EC. The primary end points studied were overall survival (OS) and disease-free survival (DFS). In addition to detailed pathology review, we evaluated prognostic variables associated with survival. RESULTS: Esophagectomy was performed in 100 patients (79 men, 21 women; median age, 68 years) for T1 EC, comprising adenocarcinoma, 91; squamous, 9; intramucosal (T1a), 29; and submucosal (T1b), 71. The 30-day mortality was 0%. Resection margins were microscopically negative in 99 patients (99%). N1 disease was present in 21 (T1a, 2 of 29 [7%]; T1b, 19 of 71 [27%]), associated high-grade dysplasia in 64 (64%), and angiolymphatic invasion in 19 (19%). At a median follow-up of 66 months, estimated 5-year OS was 62% and 3-year DFS was 80% for all patients (including N1). Nodal status and tumor size were significantly associated with OS and DFS, respectively. CONCLUSIONS: Esophagectomy can be performed safely in patients with T1 EC with good long-term results. Many patients with T1 EC have several risk factors that may preclude adequate treatment with endoscopic therapy. Further prospective studies are required to evaluate endoscopic therapies. Esophagectomy should continue to remain the standard treatment in patients with T1 EC.
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: C Ell; A May; L Gossner; O Pech; E Günter; G Mayer; R Henrich; M Vieth; H Müller; G Seitz; M Stolte Journal: Gastroenterology Date: 2000-04 Impact factor: 22.682
Authors: T W Rice; E H Blackstone; J R Goldblum; M M DeCamp; S C Murthy; G W Falk; A H Ormsby; L A Rybicki; J E Richter; D J Adelstein Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: K K Krishnadath; K K Wang; K Taniguchi; T J Sebo; N S Buttar; M A Anderson; L S Lutzke; W Liu Journal: Gastroenterology Date: 2000-09 Impact factor: 22.682
Authors: Nasser K Altorki; Paul C Lee; Yaakov Liss; Danish Meherally; Robert J Korst; Paul Christos; Madhu Mazumdar; Jeffrey L Port Journal: Ann Surg Date: 2008-03 Impact factor: 12.969
Authors: James D Luketich; Miguel Alvelo-Rivera; Percival O Buenaventura; Neil A Christie; James S McCaughan; Virginia R Litle; Philip R Schauer; John M Close; Hiran C Fernando Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: James D Luketich; Arjun Pennathur; Omar Awais; Ryan M Levy; Samuel Keeley; Manisha Shende; Neil A Christie; Benny Weksler; Rodney J Landreneau; Ghulam Abbas; Matthew J Schuchert; Katie S Nason Journal: Ann Surg Date: 2012-07 Impact factor: 12.969
Authors: Andrew Feber; Liqiang Xi; Arjun Pennathur; William E Gooding; Santhoshi Bandla; Maoxin Wu; James D Luketich; Tony E Godfrey; Virginia R Litle Journal: Ann Thorac Surg Date: 2011-03-21 Impact factor: 4.330
Authors: Cadman L Leggett; Jason T Lewis; Tsung Teh Wu; Cathy D Schleck; Alan R Zinsmeister; Kelly T Dunagan; Lori S Lutzke; Kenneth K Wang; Prasad G Iyer Journal: Clin Gastroenterol Hepatol Date: 2014-08-20 Impact factor: 11.382
Authors: Michael F Nentwich; Katharina von Loga; Matthias Reeh; Faik G Uzunoglu; Andreas Marx; Jakob R Izbicki; Dean Bogoevski Journal: J Gastrointest Surg Date: 2013-10-04 Impact factor: 3.452
Authors: Daniela Molena; Francisco Schlottmann; Joshua A Boys; Shanda H Blackmon; Karen J Dickinson; Christy M Dunst; Wayne L Hofstetter; Michal J Lada; Brian E Louie; Benedetto Mungo; Thomas J Watson; Steven R DeMeester Journal: J Gastrointest Surg Date: 2016-08-25 Impact factor: 3.452
Authors: N J O'Farrell; J V Reynolds; N Ravi; J O Larkin; V Malik; G F Wilson; C Muldoon; D O'Toole Journal: Ir J Med Sci Date: 2012-12-16 Impact factor: 1.568